HIF-2α Promotes Hypoxic Cell Proliferation by Enhancing c-Myc Transcriptional Activity

Cancer Cell

Volumn 11, Issue 4, 2007, Pages 335-347

  Gordan, John D ^a,b   Bertout, Jessica A ^a,c   Hu, Cheng Jun ^a,b   Diehl, J Alan ^a,b   Simon, M Celeste ^a,b,d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA SCHOOL OF VETERINARY MEDICINE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

DNA

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MAX PROTEIN; MYC PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR MIZ1; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; BASIC HELIX LOOP HELIX LEUCINE ZIPPER TRANSCRIPTION FACTOR; HIF1A PROTEIN, HUMAN; MAX PROTEIN, MOUSE; MESSENGER RNA; MIZ1 PROTEIN, MOUSE; MOP2 PROTEIN, HUMAN; NUCLEAR PROTEIN; PROTEIN INHIBITOR OF ACTIVATED STAT; TRANSACTIVATOR PROTEIN; VON HIPPEL LINDAU PROTEIN;

ANIMAL CELL; ARTICLE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; FIBROBLAST; GENE ACTIVATION; GENE CONTROL; GENE EXPRESSION REGULATION; GENE REPRESSION; HUMAN; HUMAN CELL; HYPOXIC CELL; KIDNEY CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DNA BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION INITIATION; TUMOR SUPPRESSOR GENE; VHL GENE; ANIMAL; CELL CULTURE; CELL CYCLE; CELL HYPOXIA; CELL STRAIN 3T3; CHROMATIN IMMUNOPRECIPITATION; COLON TUMOR; CYTOLOGY; EMBRYO; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MOUSE MUTANT; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; CELL CYCLE; CELL HYPOXIA; CELL PROLIFERATION; CELLS, CULTURED; CHROMATIN IMMUNOPRECIPITATION; COLONIC NEOPLASMS; EMBRYO; FIBROBLASTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MICE, KNOCKOUT; NIH 3T3 CELLS; NUCLEAR PROTEINS; PROMOTER REGIONS (GENETICS); PROTEIN INHIBITORS OF ACTIVATED STAT; PROTO-ONCOGENE PROTEINS C-MYC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SP1 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 34047156190     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2007.02.006     Document Type: Article

References (49)

1. Acker T., Diez-Juan A., Aragones J., Tjwa M., Brusselmans K., Moons L., Fukumura D., Moreno-Murciano M.P., Herbert J.M., Burger A., et al. Genetic evidence for a tumor suppressor role of HIF-2alpha. Cancer Cell 8 (2005) 131-141
2. Adhikary S., and Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat. Rev. Mol. Cell Biol. 6 (2005) 635-645
3. Alt J.R., Cleveland J.L., Hannink M., and Diehl J.A. Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev. 14 (2000) 3102-3114
4. Baba M., Hirai S., Yamada-Okabe H., Hamada K., Tabuchi H., Kobayashi K., Kondo K., Yoshida M., Yamashita A., Kishida T., et al. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through hypoxia-inducible factor. Oncogene 22 (2003) 2728-2738
5. Bouchard C., Thieke K., Maier A., Saffrich R., Hanley-Hyde J., Ansorge W., Reed S., Sicinski P., Bartek J., and Eilers M. Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. EMBO J. 18 (1999) 5321-5333
6. Carmeliet P., Dor Y., Herbert J.M., Fukumura D., Brusselmans K., Dewerchin M., Neeman M., Bono F., Abramovitch R., Maxwell P., et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394 (1998) 485-490
7. Coller H.A., Grandori C., Tamayo P., Colbert T., Lander E.S., Eisenman R.N., and Golub T.R. Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc. Natl. Acad. Sci. USA 97 (2000) 3260-3265
8. Compernolle V., Brusselmans K., Acker T., Hoet P., Tjwa M., Beck H., Plaisance S., Dor Y., Keshet E., Lupu F., et al. Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat. Med. 8 (2002) 702-710
9. Covello K.L., Simon M.C., and Keith B. Targeted replacement of hypoxia-inducible factor-1alpha by a hypoxia-inducible factor-2alpha knock-in allele promotes tumor growth. Cancer Res. 65 (2005) 2277-2286
10. Covello K.L., Kehler J., Yu H., Gordan J.D., Arsham A.M., Hu C.J., Labosky P.A., Simon M.C., and Keith B. HIF-2alpha regulates Oct-4: Effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev. 20 (2006) 557-570
11. Ema M., Taya S., Yokotani N., Sogawa K., Matsuda Y., and Fujii-Kuriyama Y. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. Proc. Natl. Acad. Sci. USA 94 (1997) 4273-4278
12. Erler J.T., Bennewith K.L., Nicolau M., Dornhofer N., Kong C., Le Q.T., Chi J.T., Jeffrey S.S., and Giaccia A.J. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440 (2006) 1222-1226
13. Fernandez P.C., Frank S.R., Wang L., Schroeder M., Liu S., Greene J., Cocito A., and Amati B. Genomic targets of the human c-Myc protein. Genes Dev. 17 (2003) 1115-1129
14. Gardner L.B., Li Q., Park M.S., Flanagan W.M., Semenza G.L., and Dang C.V. Hypoxia inhibits G1/S transition through regulation of p27 expression. J. Biol. Chem. 276 (2001) 7919-7926
15. Giatromanolaki A., Koukourakis M.I., Sivridis E., Turley H., Talks K., Pezzella F., Gatter K.C., and Harris A.L. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br. J. Cancer 85 (2001) 881-890
16. Gidekel S., Pizov G., Bergman Y., and Pikarsky E. Oct-3/4 is a dose-dependent oncogenic fate determinant. Cancer Cell 4 (2003) 361-370
17. Goda N., Ryan H.E., Khadivi B., McNulty W., Rickert R.C., and Johnson R.S. Hypoxia-inducible factor 1alpha is essential for cell cycle arrest during hypoxia. Mol. Cell. Biol. 23 (2003) 359-369
18. Green S.L., Freiberg R.A., and Giaccia A.J. p21(Cip1) and p27(Kip1) regulate cell cycle reentry after hypoxic stress but are not necessary for hypoxia-induced arrest. Mol. Cell. Biol. 21 (2001) 1196-1206
19. Gunaratnam L., Morley M., Franovic A., de Paulsen N., Mekhail K., Parolin D.A., Nakamura E., Lorimer I.A., and Lee S. Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells. J. Biol. Chem. 278 (2003) 44966-44974
20. Holmquist-Mengelbier L., Fredlund E., Lofstedt T., Noguera R., Navarro S., Nilsson H., Pietras A., Vallon-Christersson J., Borg A., Gradin K., et al. Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. Cancer Cell 10 (2006) 413-423
21. Hopfl G., Wenger R.H., Ziegler U., Stallmach T., Gardelle O., Achermann R., Wergin M., Kaser-Hotz B., Saunders H.M., Williams K.J., et al. Rescue of hypoxia-inducible factor-1alpha-deficient tumor growth by wild-type cells is independent of vascular endothelial growth factor. Cancer Res. 62 (2002) 2962-2970
22. Hu C.J., Wang L.Y., Chodosh L.A., Keith B., and Simon M.C. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol. Cell. Biol. 23 (2003) 9361-9374
23. Iyer N.V., Kotch L.E., Agani F., Leung S.W., Laughner E., Wenger R.H., Gassmann M., Gearhart J.D., Lawler A.M., Yu A.Y., and Semenza G.L. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev. 12 (1998) 149-162
24. Kondo K., Klco J., Nakamura E., Lechpammer M., and Kaelin Jr. W.G. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 1 (2002) 237-246
25. Kondo K., Kim W.Y., Lechpammer M., and Kaelin Jr. W.G. Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol. 1 (2003) E83 10.1371/journal.pbio.0000083d
26. Koshiji M., Kageyama Y., Pete E.A., Horikawa I., Barrett J.C., and Huang L.E. HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. EMBO J. 23 (2004) 1949-1956
27. Koshiji M., To K.K., Hammer S., Kumamoto K., Harris A.L., Modrich P., and Huang L.E. HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha expression. Mol. Cell 17 (2005) 793-803
28. Lum J.J., Bui T., Gruber M., Gordan J.D., DeBerardinis R.J., Covello K.L., Simon M.C., and Thompson C.B. The transcription Factor HIF-1α is a growth factor-dependent regulator of intracellular glucose fate. Genes Dev. (2007) in press
29. Mack F.A., Patel J.H., Biju M.P., Haase V.H., and Simon M.C. Decreased growth of Vhl-/- fibrosarcomas is associated with elevated levels of cyclin kinase inhibitors p21 and p27. Mol. Cell. Biol. 25 (2005) 4565-4578
30. Mandriota S.J., Turner K.J., Davies D.R., Murray P.G., Morgan N.V., Sowter H.M., Wykoff C.C., Maher E.R., Harris A.L., Ratcliffe P.J., and Maxwell P.H. HIF activation identifies early lesions in VHL kidneys: Evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 1 (2002) 459-468
31. Mansfield K.D., Guzy R.D., Pan Y., Young R.M., Cash T.P., Schumacker P.T., and Simon M.C. Mitochondrial dysfunction resulting from loss of cytochrome c impairs cellular oxygen sensing and hypoxic HIF-alpha activation. Cell Metab. 1 (2005) 393-399
32. Maranchie J.K., Vasselli J.R., Riss J., Bonifacino J.S., Linehan W.M., and Klausner R.D. The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 1 (2002) 247-255
33. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., Wykoff C.C., Pugh C.W., Maher E.R., and Ratcliffe P.J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 (1999) 271-275
34. Nilsson J.A., and Cleveland J.L. Myc pathways provoking cell suicide and cancer. Oncogene 22 (2003) 9007-9021
35. Peng J., Zhang L., Drysdale L., and Fong G.H. The transcription factor EPAS-1/hypoxia-inducible factor 2alpha plays an important role in vascular remodeling. Proc. Natl. Acad. Sci. USA 97 (2000) 8386-8391
36. Pugh C.W., and Ratcliffe P.J. Regulation of angiogenesis by hypoxia: Role of the HIF system. Nat. Med. 9 (2003) 677-684
37. Qu L., Huang S., Baltzis D., Rivas-Estilla A.M., Pluquet O., Hatzoglou M., Koumenis C., Taya Y., Yoshimura A., and Koromilas A.E. Endoplasmic reticulum stress induces p53 cytoplasmic localization and prevents p53-dependent apoptosis by a pathway involving glycogen synthase kinase-3beta. Genes Dev. 18 (2004) 261-277
38. Raval R.R., Lau K.W., Tran M.G., Sowter H.M., Mandriota S.J., Li J.L., Pugh C.W., Maxwell P.H., Harris A.L., and Ratcliffe P.J. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol. Cell. Biol. 25 (2005) 5675-5686
39. Ryan H.E., Lo J., and Johnson R.S. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J. 17 (1998) 3005-3015
40. Ryan H.E., Poloni M., McNulty W., Elson D., Gassmann M., Arbeit J.M., and Johnson R.S. Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. Cancer Res. 60 (2000) 4010-4015
41. Scortegagna M., Ding K., Oktay Y., Gaur A., Thurmond F., Yan L.J., Marck B.T., Matsumoto A.M., Shelton J.M., Richardson J.A., et al. Multiple organ pathology, metabolic abnormalities and impaired homeostasis of reactive oxygen species in Epas1-/- mice. Nat. Genet. 35 (2003) 331-340
42. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3 (2003) 721-732
43. Tian H., McKnight S.L., and Russell D.W. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev. 11 (1997) 72-82
44. Tian H., Hammer R.E., Matsumoto A.M., Russell D.W., and McKnight S.L. The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development. Genes Dev. 12 (1998) 3320-3324
45. To K.K., Sedelnikova O.A., Samons M., Bonner W.M., and Huang L.E. The phosphorylation status of PAS-B distinguishes HIF-1alpha from HIF-2alpha in NBS1 repression. EMBO J. 25 (2006) 4784-4794
46. Twardzik D.R., Todaro G.J., Marquardt H., Reynolds Jr. F.H., and Stephenson J.R. Transformation induced by Abelson murine leukemia virus involves production of a polypeptide growth factor. Science 216 (1982) 894-897
47. Wang V., Davis D.A., Haque M., Huang L.E., and Yarchoan R. Differential gene up-regulation by hypoxia-inducible factor-1alpha and hypoxia-inducible factor-2alpha in HEK293T cells. Cancer Res. 65 (2005) 3299-3306
48. Wiesener M.S., Jurgensen J.S., Rosenberger C., Scholze C.K., Horstrup J.H., Warnecke C., Mandriota S., Bechmann I., Frei U.A., Pugh C.W., et al. Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs. FASEB J. 17 (2003) 271-273
49. Yoshimura H., Dhar D.K., Kohno H., Kubota H., Fujii T., Ueda S., Kinugasa S., Tachibana M., and Nagasue N. Prognostic impact of hypoxia-inducible factors 1alpha and 2alpha in colorectal cancer patients: Correlation with tumor angiogenesis and cyclooxygenase-2 expression. Clin. Cancer Res. 10 (2004) 8554-8560